Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus CEFADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus CEFADYL.
ANSPOR vs CEFADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic